SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

SION-2222

SION·Sionna Therapeutics, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
Time to market
At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
Why 5/10
The next hard catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027 (about 4 months away). This is a milestone event, not a binary readout, and the actual Phase 2a topline data is likely 12+ months further out. ImpactScore of 5 reflects that this is a meaningful milestone for a single-asset company but not a binary catalyst.
Actionable Insight NEUTRAL

The next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.

Price Chart

Loading chart...

Executive Summary

SION-2222 (galicaftor) is a TMD1-directed CFTR corrector being developed by Sionna Therapeutics (NASDAQ: SION) as part of a dual combination therapy with SION-451 (an NBD1 stabilizer) for cystic fibrosis. The drug completed Phase 1 testing in healthy volunteers with a tolerable safety profile, and the company plans to initiate the AscenSION CF Phase 2a proof-of-concept trial in Q1 2027. This program became Sionna's sole focus after its lead candidate SION-719 failed a Phase 2a trial in August 2026, causing the stock to crash roughly 92% from about $50 to around $3.70. The company cut 46% of its workforce in September 2026 and holds $249.8M in cash funding operations into H2 2029. SION-2222 has never been tested in CF patients, and the dual combination faces the challenge of competing against Vertex's dominant Trikafta franchise.

How It Works

SION-2222 (galicaftor) is a CFTR corrector that targets a specific region of a protein called the transmembrane domain 1 (TMD1). In cystic fibrosis, the CFTR protein is defective and cannot properly transport salt and water in cells. SION-2222 is designed to fix the shape of the CFTR protein so it can function more normally. It is being developed as part of a two-drug combination with SION-451, an NBD1 stabilizer that targets a different part of the same protein, with the goal of providing a standalone treatment for cystic fibrosis that could help patients who do not respond adequately to existing therapies like Vertex's Trikafta.

Trial Status

A Phase 1 healthy-volunteer trial (NCT07035990) evaluated safety, tolerability and pharmacokinetics of SION-451 in dual combination with SION-2222; topline data reported August 10, 2026 showed the SION-451 + SION-2222 cohorts were generally well tolerated with mostly mild-to-moderate adverse events and no serious adverse events, though two participants discontinued due to elevated liver function tests and flu-like symptoms. The AscenSION CF Phase 2a proof-of-concept trial in CF patients is expected to initiate in Q1 2027, supported by post hoc PreciSION CF analyses of SION-719.

The Two-Sided Case

▲ Bull Case5
SION-2222 (galicaftor) is a TMD1-directed CFTR corrector that, combined with the NBD1 stabilizer SION-451, showed a well-tolerated safety profile in Phase 1 healthy volunteer dosing; in the SION-451 + SION-2222 cohorts most treatment-emergent adverse events were mild to moderate and no serious adverse events were reported.
The company has $249.8M in cash and securities as of Q3 2026, funding operations into H2 2029 and removing near-term dilution risk while the dual combination advances.
Sionna cut 46% of its workforce in September 2026 to focus exclusively on the SION-451 + SION-2222 dual combination, concentrating all resources on this single program.
Preclinical data presented at the 2026 NACFC and at the 48th European Cystic Fibrosis Conference showed that NBD1 stabilizer combinations could enable full CFTR correction in CFHBE models, potentially addressing a broad CF population.
Several institutional investors (Adage Capital, Goldman Sachs, Millennium Management) added or doubled their SION positions in Q2 2026 before the crash.
▼ Bear Case5
SION-2222 has never been tested in CF patients; the Phase 1 trial was only in healthy volunteers, so efficacy is entirely unproven.
The company's prior lead candidate SION-719 failed its Phase 2a endpoint in August 2026, eroding confidence in the NBD1 stabilizer platform and raising questions about whether SION-451 (the partner drug) will work.
Vertex Pharmaceuticals (VRTX) dominates the CF market with Trikafta, and Sionna's dual combination would need to show a compelling efficacy and safety profile to compete or carve out a niche.
The stock has already crashed ~92% from pre-failure levels, and analyst consensus shifted to mostly Hold/Neutral after the SION-719 failure, with a mean price target of $21 but a median of just $6.
RA Capital Management, a major holder, sold over 3.4 million shares at $6.32 in September 2026, signaling insider skepticism even after the crash.

Upcoming Catalysts

  • Initiation of the AscenSION CF Phase 2a proof-of-concept trial for SION-451 + SION-2222, expected Q1 2027
  • Clinical and nonclinical data presentations at medical conferences (2026 NACFC data already presented)
  • Q3 2026 earnings call scheduled around November 11, 2026 (earnings calendar event)
  • Any further restructuring, partnership or financing news given the single-asset focus

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sionna Therapeutics, Inc. PRESS-RELEASE SION ·Originating report

Sources · 9

Hover a chip for the title
1 markets.financialcontent.com2 menafn.com3 msn.com4 manilatimes.net5 markets.businessinsider.com6 seekingalpha.com7 insidermonkey.com8 247wallst.com9 nasdaq.com